about
Effects of hemodiafiltration and high flux hemodialysis on nerve excitability in end-stage kidney diseaseThe Relationship between Dyslipidemia and Acute Axonal Function in Type 2 Diabetes Mellitus In VivoPediatric chemotherapy induced peripheral neuropathy: A systematic review of current knowledge.Paclitaxel-induced neuropathy: potential association of MAPT and GSK3B genotypesLong-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibilitySensory nerve excitability and neuropathy in end stage kidney diseaseEffects of axonal ion channel dysfunction on quality of life in type 2 diabetesRiluzole, neuroprotection and amyotrophic lateral sclerosis.Mechanisms of axonal dysfunction in diabetic and uraemic neuropathies.Bell's palsy: aetiology, clinical features and multidisciplinary care.Ion Channel Modulation as a Therapeutic Approach in Multiple Sclerosis.Altered axonal excitability properties in facial palsy.Nerve excitability in the rat forelimb: a technique to improve translational utility.Neurophysiological and clinical outcomes in chemotherapy-induced neuropathy in cancer.Assessment of axonal excitability properties in two branches of the human facial nerve.Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey.Motor cortex excitability in acute cerebellar infarct.Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity.In vivo evidence of reduced nodal and paranodal conductances in type 1 diabetes.Immune dysregulation in patients with carpal tunnel syndrome.Early, progressive, and sustained dysfunction of sensory axons underlies paclitaxel-induced neuropathy.Oxaliplatin-induced lhermitte's phenomenon as a manifestation of severe generalized neurotoxicity.Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy.Evidence for a causal relationship between hyperkalaemia and axonal dysfunction in end-stage kidney disease.Axonal dysfunction prior to neuropathy onset in type 1 diabetes.Sleep-Disordered Breathing in People with Multiple Sclerosis: Prevalence, Pathophysiological Mechanisms, and Disease Consequences.Changes in human sensory axonal excitability induced by an ischaemic insult.Central sleep apnea in multiple sclerosis: a pilot study.Multimodal quantitative examination of nerve function in colorectal cancer patients prior to chemotherapy.The clinical meaning of walking speed as measured by the timed 25-foot walk in patients with multiple sclerosis.Exploring the Evolution of Cortical Excitability Following Acute Stroke.The Effect of Diabetes on Cortical Function in Stroke: Implications for Poststroke Plasticity.Randomized, Controlled Trial of the Effect of Dietary Potassium Restriction on Nerve Function in CKD.Motor unit remodelling in multifocal motor neuropathy: The importance of axonal loss.Utility of maximum perfusion intensity as an ultrasonographic marker of intraneural blood flow.Effects of hemodialysis on intraneural blood flow in end-stage kidney disease.Fampridine treatment and walking distance in multiple sclerosis: A randomised controlled trial.Haemodialysis alters peripheral nerve morphology in end-stage kidney disease.Effect of fampridine on axonal excitability in multiple sclerosis.Transynaptic changes evident in peripheral axonal function after acute cerebellar infarct.
P50
Q28487895-12B03343-C498-49A4-9B7E-7055CB1B1864Q28551366-E1BE9114-38E1-4A51-A4E0-62FCD5264812Q30245115-E7328E28-B8A0-4AB4-8944-1D6E19691B44Q35191233-495B8ADB-CEFF-4BEA-BE5A-A1E29FC0CE8EQ35584874-8C45049D-4538-4043-BC31-A409E6BC1AC4Q36142247-A730F01A-133F-43A2-845C-1506995FA758Q36782662-17E9FA6F-52FD-4508-8E97-25186641A92FQ37727244-047E7783-BDC1-4A06-922C-58D160CB57B0Q38107576-3CFD5E76-1788-4F79-B469-9DA19704431CQ38413208-7FC0DDC4-DA29-4A9C-BA86-C4DF43CCD8CCQ38618800-16FF83FA-D55D-4D4E-B529-36424854A463Q38689339-2FDF98AE-1E58-4115-BD33-A46115514C56Q39258559-1CD1A646-A0D5-42E8-B546-1FA22C6DC55EQ39311528-1129FBF3-B178-46F2-8F07-6A38EBF24572Q39332031-6C9F0CB3-4A2C-4E87-BE80-9D854AB9579EQ39356105-FA083C9A-8D91-43FB-89BD-BD1EA0858FC2Q39409042-3EDD135D-C8FE-4F1A-A7CE-E1B6F8C75039Q40008155-CD0C8A31-745A-4C5E-A986-CACA8989661BQ40150442-BF84D9A2-3B2E-4B61-9FE2-9798B5E7A714Q41423404-94DE1E8E-71FE-441F-B67B-EE6DED4C17C8Q42750577-4497975F-15EC-4C51-BB1B-684D5E3ADCCBQ43218131-46CD0DF4-EDDA-4A50-AD1B-BFE65DDD4D96Q43278321-5E0AB119-96BB-4C7E-BC18-CAD8A8256273Q44611162-2B673A73-541D-4076-A555-AD1301863A1CQ46074057-4C349680-DE36-4C3B-AD42-5B3E05DBAA99Q47548263-BF8E7DB2-3DB3-46F6-9527-ED1E43E2F20FQ47624621-A604EEA6-150A-4A6E-9CFE-D35AB4A48737Q47784032-5FBD2DC9-9930-4488-8A3E-018456C742B1Q48020601-3D9D03EA-A681-424F-8AC9-B4986D5F6F69Q48066576-C1E74C6E-0DF6-4419-B8C6-BE5B3D578723Q48091830-93F7981D-ED2E-4DE5-93DB-D94157F40DECQ48095947-D3A783B5-276A-4841-8024-7ECBA47A24B9Q48118200-C5998D1B-66B7-4CC8-A20F-A2A8D0B8C5F5Q48141508-3B8775B2-3C95-46A4-A9EA-9365B30B91C3Q48222086-80B8D49C-652D-4321-BF14-8B30FFB40752Q48362477-97D27007-467E-4C1C-A2C9-944181F7354BQ48421690-E0094217-28AC-4DA2-9392-F3610668A3FCQ48478116-60E8A50B-4E2F-430E-8CAA-8341D1E9AE87Q48682236-F10167CA-BEA1-4487-8B1B-658DD8F4EC99Q48710388-2B6D4E2C-F38F-46A3-BFAF-CB873FF2240B
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Arun V Krishnan
@en
Arun V Krishnan
@nl
type
label
Arun V Krishnan
@en
Arun V Krishnan
@nl
prefLabel
Arun V Krishnan
@en
Arun V Krishnan
@nl
P31
P496
0000-0001-8883-8825